TORRENT PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of TORRENT PHARMACEUTICALS have increased by 6.29% YoY .
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has decreased by -19.88 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
TORRENT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500420|NSE : TORNTPHARM]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹8,508 Cr | ₹8,005 Cr | ₹7,939 Cr | ₹7,673 Cr | ₹5,950 Cr |
| Expenses | ₹6,077 Cr | ₹5,524 Cr | ₹5,769 Cr | ₹5,696 Cr | ₹4,609 Cr |
| Operating Profit (Excl OI) | ₹2,431 Cr | ₹2,480 Cr | ₹2,170 Cr | ₹1,976 Cr | ₹1,341 Cr |
| Other Income | ₹197 Cr | ₹57 Cr | ₹121 Cr | ₹64 Cr | ₹307 Cr |
| Interest | ₹255 Cr | ₹353 Cr | ₹451 Cr | ₹504 Cr | ₹308 Cr |
| Depreciation | ₹662 Cr | ₹658 Cr | ₹654 Cr | ₹618 Cr | ₹409 Cr |
| Profit Before Tax | ₹1,226 Cr | ₹1,526 Cr | ₹1,187 Cr | ₹562 Cr | ₹931 Cr |
| Profit After Tax | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr | ₹436 Cr | ₹678 Cr |
| Consolidated Net Profit | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr | ₹436 Cr | ₹678 Cr |
| Earnings Per Share (Rs) | ₹36.79 | ₹45.92 | ₹73.97 | ₹60.55 | ₹25.78 |
| PAT Margin (%) | 7.61 | 5.11 | 8.41 | 6.85 | 3.00 |
| ROE(%) | 20.50 | 13.18 | 23.49 | 21.47 | 9.34 |
| ROCE(%) | 20.32 | 14.35 | 17.62 | 15.28 | 9.75 |
| Total Debt/Equity(x) | 0.85 | 0.68 | 0.83 | 1.21 | 1.28 |
Key Financials |
||
| Market Cap | : | ₹ 91,044.8 Cr |
| Revenue (TTM) | : | ₹ 10,474.0 Cr |
| Net Profit(TTM) | : | ₹ 1,494.0 Cr |
| EPS (TTM) | : | ₹ 44.1 |
| P/E (TTM) | : | 60.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| CIPLA | 4.1% | -4.8% | 55.6% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| LUPIN | 0.6% | 0.5% | 127.2% |
| AUROBINDO PHARMA | 5.1% | 10.9% | 87.1% |
TORRENT PHARMACEUTICALS Revenues
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 6.29 % |
| 5 Yr CAGR | 9.35 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹8,508 Cr | 6.29 | |
| Mar2022 | ₹8,005 Cr | 0.82 | |
| Mar2021 | ₹7,939 Cr | 3.47 | |
| Mar2020 | ₹7,673 Cr | 28.96 | |
| Mar2019 | ₹5,950 Cr | - | |
TORRENT PHARMACEUTICALS Operating Profit
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | -1.97 % |
| 5 Yr CAGR | 16.04 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹2,431 Cr | -1.97 | |
| Mar2022 | ₹2,480 Cr | 14.27 | |
| Mar2021 | ₹2,170 Cr | 9.81 | |
| Mar2020 | ₹1,976 Cr | 47.38 | |
| Mar2019 | ₹1,341 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -7.75 % |
| 5 Yr CAGR | 6.12 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 28.58% | -7.75 | |
| Mar2022 | 30.98% | 13.31 | |
| Mar2021 | 27.34% | 6.13 | |
| Mar2020 | 25.76% | 14.29 | |
| Mar2019 | 22.54% | - | |
TORRENT PHARMACEUTICALS Profit After Tax
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | -37.92 % |
| 5 Yr CAGR | 3.47 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹777 Cr | -37.92 | |
| Mar2022 | ₹1,252 Cr | 22.17 | |
| Mar2021 | ₹1,025 Cr | 134.88 | |
| Mar2020 | ₹436 Cr | -35.66 | |
| Mar2019 | ₹678 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 48.92 % |
| 5 Yr CAGR | 26.20 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 7.61 % | 48.92 | |
| Mar2022 | 5.11 % | -39.24 | |
| Mar2021 | 8.41 % | 22.77 | |
| Mar2020 | 6.85 % | 128.33 | |
| Mar2019 | 3 % | - | |
TORRENT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | -19.88 % |
| 5 Yr CAGR | 9.30 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹37 | -19.88 | |
| Mar2022 | ₹46 | -37.92 | |
| Mar2021 | ₹74 | 22.16 | |
| Mar2020 | ₹61 | 134.87 | |
| Mar2019 | ₹26 | - | |
TORRENT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 41.60 % |
| 5 Yr CAGR | 20.15 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 20.32% | 41.60 | |
| Mar2022 | 14.35% | -18.56 | |
| Mar2021 | 17.62% | 15.31 | |
| Mar2020 | 15.28% | 56.72 | |
| Mar2019 | 9.75% | - | |
TORRENT PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹2,690.5 |
| Current MarketCap | : | ₹ 91,044.8 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TORRENT PHARMACEUTICALS | 3.9% |
5.1% |
66.1% |
| SENSEX | 0.9% |
1.5% |
23.6% |
TORRENT PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
| S&P BSE MID CAP | 4% | 7.6% | 67.4% |
| S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
| S&P BSE ALLCAP | 2.3% | 5% | 41.4% |
| S&P BSE 500 | 2.1% | 4.5% | 39.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY NEXT 50 | 3.6% | 8.9% | 66.9% |
| NIFTY HEALTHCARE | 3.2% | 2.5% | 51.3% |
| NIFTY PHARMA | 3.2% | 2.2% | 51.4% |
| NIFTY 100 ALPHA 30 | 3% | 9% | 71.5% |
| NIFTY500 MULTICAP 50:25:25 | 2.8% | 6.7% | 49.4% |
You may also like the below Video Courses
FAQ about TORRENT PHARMACEUTICALS Financials
How the annual revenues of TORRENT PHARMACEUTICALS have changed ?
The Revenues of TORRENT PHARMACEUTICALS have increased by 6.29% YoY .
How the Earnings per Share (EPS) of TORRENT PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has decreased by -19.88 % YoY .
Check out Intrinsic Value of Peers of TORRENT PHARMACEUTICALS
Compare Stock Analytics of Peers of TORRENT PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
